Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Covington
Novartis
Citi
Moodys
Healthtrust
Dow
Daiichi Sankyo
Express Scripts
Julphar

Generated: October 22, 2017

DrugPatentWatch Database Preview

ENDOMETRIN Drug Profile

« Back to Dashboard

What is the patent landscape for Endometrin, and when can generic versions of Endometrin launch?

Endometrin is a drug marketed by Ferring and is included in one NDA. There are three patents protecting this drug.

This drug has twelve patent family members in nine countries and one supplementary protection certificate in one country.

The generic ingredient in ENDOMETRIN is progesterone. There are fifty-two drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the progesterone profile page.

Summary for Tradename: ENDOMETRIN

US Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list70
Clinical Trials: see list11
Patent Applications: see list9,707
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ENDOMETRIN at DailyMed

Pharmacology for Tradename: ENDOMETRIN

Ingredient-typeProgesterone
Drug ClassProgesterone
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ferring
ENDOMETRIN
progesterone
INSERT;VAGINAL022057-001Jun 21, 2007RXYesYes► Subscribe► Subscribe ► Subscribe
Ferring
ENDOMETRIN
progesterone
INSERT;VAGINAL022057-001Jun 21, 2007RXYesYes► Subscribe► Subscribe ► Subscribe
Ferring
ENDOMETRIN
progesterone
INSERT;VAGINAL022057-001Jun 21, 2007RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ENDOMETRIN

Country Document Number Estimated Expiration
European Patent Office1131052► Subscribe
Israel127129► Subscribe
Canada2568823► Subscribe
European Patent Office2386291► Subscribe
Japan4667601► Subscribe
Japan2011026335► Subscribe
World Intellectual Property Organization (WIPO)0028970► Subscribe
Spain2390959► Subscribe
Australia1176200► Subscribe
Japan2002529494► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ENDOMETRIN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0037Belgium► SubscribePRODUCT NAME: OESTROGENES EQUINS CONJUGUES; ACETATE DE MEDROXYPROGESTERONE; NAT. REGISTRATION NO/DATE: NL 19569 19950301; FIRST REGISTRATION: CH - 52647 01 010 19940826
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Cipla
Cerilliant
UBS
McKesson
Johnson and Johnson
US Army
Fish and Richardson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot